MannKind Corporation (NASDAQ:MNKD) released the results from its most recently completed quarter, posting net losses of 14 cents per share or $52.1 million. Analysts had been expecting losses of 13 cents per share. In the same quarter a year ago, the drug maker posted net losses of 15 cents per share or $41 million.
Breaking down MannKind’s results
The drug maker reported rising expenses due to an increase in general and administrative expenses. The company said total operating expenses were $41.4 million compared to $36.4 million in the same quarter a year ago. MannKind Corporation (NASDAQ:MNKD) reported $26.2 million in research and development expenses, a decline from $26.4 million in last year’s first quarter.
RV Capital Co-Investor Letter for the first half ended June 2022. Q2 2022 hedge fund letters, conferences and more Dear Co-Investors,